The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer

Breast Cancer Research and Treatment

Volumn 44, Issue 2, 1997, Pages 123-133

  Keen, J C ^a,d   Dixon, J M ^a   Miller, E P ^a   Cameron, D A ^a   Chetty, U ^a   Hanby, A ^b   Bellamy, C ^c   Miller, W R ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ROYAL COLLEGE OF SURGEONS OF ENGLAND   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d St Columba's Hospice   (United Kingdom)

Author keywords

Bcl 2; Breast cancer; Ki S1; Tamoxifen

Indexed keywords

ANTIESTROGEN; TAMOXIFEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CELL DEATH; CELL PROLIFERATION; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOPSY; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 0030914830     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005796915388     Document Type: Article

References (31)

1. McGiuire WL, Carbone PP, Sears ME: Estrogen Receptors in Human Breast Cancer: An Overview. Raven Press, New York, 1995, pp 1-7
2. Low SC, Dixon AR, Bell J, Ellis JO, Elston CW, Robertson JFR, Blamey RW: Tumour oestrogen receptor content allows selection of elderly patients with breast cancer for conservative tamoxifen treatment. Br J Surg 79: 1314-1316, 1992
3. Furr BJ, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127-205, 1984
4. Forrest APM, Anderson EDC, Gaskill D: Primary systemic therapy for breast cancer. Br Med Bull 47: 357-371, 1991
5. Horobin JM, Preece PE, Dewar JA, Wood RA, Cuschieri A: Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg 78: 213-217, 1991
6. Forrest APM, Levaek PA, Chetty U, Hawkins RA, Miller WR, Smyth JF, Anderson TJ: A human tumour model. Lancet 2: 840-842, 1986
7. Kreipe H, Heidebrecht HJ, Hansen S, Rohlk W, Kubbies M, Wacker HH, Tiemann M, Radzun HJ, Parwaresch R: A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1. Am J Pathol 142: 3-9, 1993
8. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: bcl-2 Is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.) 348: 334-336, 1990
9. Miyashita T, Reed JC: bcl-2 Gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52: 5407-5411, 1992
10. Lu Q-L, Poulsom R, Wong L, Hanby AM: bcl-2 Expression in adult and embryonic non-haematopoietic tissues. J Pathol 169: 431-437, 1993
11. Hockenbery D, Zutter M, Hickey W, Nahm M, Korsmeyer SJ: Bcl-2 protein is topographically restricted in tissues characterised by apoptolic cell death. Proc Natl Acad Sci USA 88: 6961-6965, 1991
12. Colombel M, Symmans F, Gil Sm O'Toole KM, Chopin D, Benson M, Olson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400, 1993
13. Hsu SM, Raine L, Fanger H: Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580, 1981
14. Shi S-R, Key ME, Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748, 1991
15. EBCTCG (Early Breast Cancer Trialists' Collaborative Group): Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339: 1-15, 71-85, 1992
16. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowselt M, McKinna JA, Nash AG, Sinnett HD, Tillyer CR, Treleaven JG: A pilot trial to evaluate the acute toxicology and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60: 126-131, 1989
17. Anderson EDC, Forrest APM, Hawkins RA, Anderson TJ, Leonard RCF, Chetty U: Primary systemic therapy for operable breast cancer. Br J Cancer 63: 561-566, 1991
18. Gaskell DJ, Hawkins RA, de Carteret S, Chetty U, Sangster K, Forrest APM: Indications for primary tamoxifen therapy in elderly women with breast cancer. Br J Surg 79: 1317-1320, 1992
19. Sutherland RL, Green MD, Hall RE, Reddel RR, Taylor IW: Tamoxifen induces accumulation of MCF-7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol 19: 615-621, 1983
20. Ferguson DJP, Anderson TJ: Ultrastructural observations on cell death by apoptosis in the 'resting' human breast. Virchows Arch 393: 193-203, 1981
21. Warri AM, Huovinen RL, Laine AM, Martikainen PM, Harkonen PL: Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 85: 1412-1418, 1993
22. Aaltomaa S, Lipponen P, Syrjanen K: Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nuclear antigen (PCNA) immunostaining. Anticancer Res 12: 1281-1286, 1992
23. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW: Relationship between EGF-R, c-erB B-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A: 1018-1023, 1993
24. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL: bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69: 135-139, 1994
25. Nathan B, Gusterson B, Jadayel D, O'Hare M, Anbazhagan R, Jayatilake H, Ebbs S, Micklem K, Price K, Gelber R: Expression of BCL-2 in primary breast cancer and ils correlation with tumour phenotype. Ann Oncol 5: 409-411, 1994
26. Johnston SRD, MacLennan KA, Sacks NPM, Salter J, Smith IE, Dowsett M: Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 30A: 1663-1669, 1994
27. Chan WK, Poulsom R, Lu Q-L, Patel K, Gregory W, Fisher CJ, Hanby AM: bcl-2 Expression in invasive mammary carcinoma: correlation with apoptosis, hormone receptors and p53 expression (Abstract). J Pathol 169: 153A, 1993
28. Paradiso A, Lorusso S, Tommasi F, Schittulli F, Maiello E, De Lena M: Relevance of cell kinetics to hormonal response of receptor-positive advanced breast cancer. Breast Cancer Res Treat 11: 31-36, 1988
29. Amadori D, Volpi A, Callea A, Amaducci L, Morgagni S, Magni E, Nanni O: Clinical relevance of cell kinetics in breast cancer. Ann NY Acad Sci 698: 186-192, 1993
30. Gee JMW, Robertson JFR, Ellis IAO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW, Nicolson RI: Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628, 1994
31. Clarke RB, Laidlaw LJ, Jones LJ, Howell A, Anderson E: Effect of tamoxifen on Ki67 labeling index in human breast tumours and its relationship to estrogen and progesterone receptor status. Br J Cancer 67: 606-611, 1993